Scientific Research News

BOSTON--(BUSINESS WIRE)--Foundation Medicine spotlights scientific achievements at ESMO Congress in 11 abstracts, including one oral presentation, across seven cancer types....

PHOENIX--(BUSINESS WIRE)--University of Phoenix College of Doctoral Studies announced a new white paper, “Autonomy and Competitive Edge: Mentorship as a Solution,” by Louise Underdahl, Ph.D., doctoral instructor and a research fellow with the University’s Center for Educational and Instructional Technology Research (CEITR), exploring how structured mentoring programs can help organizations address a growing crisis of worker autonomy, reduce burnout and improve retention. Drawing on findings fro...

AUSTIN, Texas--(BUSINESS WIRE)--Oticara Announces Positive Phase 2 Results Demonstrating Durable Symptom Improvement for Hard-to-Treat Post-Surgical Chronic Rhinosinusitis...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS trial in a poster presentation at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 22-26, 2025 in Boston, MA. The LIONS clinical trial (NCT06232408) is a first-...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, Massachusetts. The presentation will...

BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced two major recognitions from the Society for Clinical Data Management (SCDM), highlighting the company’s leadership in advancing data science innovation. At the 2025 SCDM Annual Conference, elluminate Assist, a generative AI-powered assistant built within eClinical Solutions’ elluminate Clinical Data Cloud®, was awarded the SCDM Innovation Award for “Advancements in Heal...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includes results from the randomized phase 3 IMvigor011 trial and from Checkmate 274. Professor Thomas Powles, lead principa...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced it will host a virtual roundtable discussion with recognized key opinion leaders in oncology. The Fore-sponsored webcast event will take place on Wednesday, October 15, 2025, at 12:00 p.m. ET. “We are honored to bring together this distinguished group of medical oncology leaders to share their perspectives on...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025...

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or...